Drug Eruption and Interactions - PHARMACEUTICAL REVIEW
Share Embed Flag
Download ePaper

Drug Eruption and Interactions - PHARMACEUTICAL REVIEW

Drug Eruption and Interactions - PHARMACEUTICAL REVIEW Drug Eruption and Interactions - PHARMACEUTICAL REVIEW

pharmareview.files.wordpress.com
from pharmareview.files.wordpress.com More from this publisher
02.06.2013 Views

(1994): Halpern SM, Arch Dermatol 130, 259 (passim) (1993): Litt JZ, Beachwood, OH (personal case) (observation) (1987): Shelley ED+, JAmAcadDermatol17, 1057 (1985): Bigby M+, JAmAcadDermatol12, 866 (1984): Stern RS+, JAMA 252, 1433 (1982): Bailin PL+, Clinics in Rheumatic Diseases WB Saunders 8, 493 (passim) Vasculitis (2001): Davidson KA+, Cutis 67, 303 (bullous leukocytoclastic) (1996): Peters F+, J Rheumatol 23, 2008 (1994): Halpern SM, Arch Dermatol 130, 259 (passim) (1992): Breathnach SM+, Adverse Drug Reactions and the Skin Blackwell, Oxford, 186 (passim) (1985): Bigby M+, JAmAcadDermatol12, 866 (1984): Stern R+, JAMA 252, 1433 (1982): Labbe A+, Ann Dermatol Venereol (French) 109, 995 Vesiculobullous eruption (1992): Breathnach SM+, Adverse Drug Reactions and the Skin Blackwell, Oxford, 186 (passim) (1988): Laing VB+, JAmAcadDermatol19, 91 (passim) Wound complications (1988): Proper SA+, JAmAcadDermatol18, 1173 Mucosal Aphthous stomatitis Gingival ulceration (

284 ICODEXTRIN Facial edema (5%) Pruritus (>5%) Rash (sic) (2003): Frampton JE+, Drugs 63(19), 2079 (5%) Vesiculobullous eruption (5%) Pain (>5%) Upper respiratory infection (15%) IDARUBICIN Synonyms: 4-demethoxydaunorubicin; 4-DMDR Trade names: Idamycin (Pfizer); Zavedos Indications: Acute myeloid leukemia Category: Antibiotic, anthracycline Half-life: 14–35 hours (oral) Clinically important, potentially hazardous interactions with: aldesleukin Reactions Skin Acral erythema (1993): Cohen PR, Cutis 51, 175 Bullous dermatitis (palms and soles) Exanthems (10%) (1998): Stuart NS+, Cancer Chemother Pharmacol 21, 351 (1997): Maloney DG+, J Clin Oncol 15, 3266 Urticaria (>10%) (1997): Maloney DG+, J Clin Oncol 15, 3266 Mucosal Mucositis (50%) (2000): Creutzig U+, Klin Padiatr 212, 163 (1986): Dodion P+, Invest New Drugs 4, 31 Stomatitis (>10%) Hair Hair – alopecia (77%) (2000): No author, Prescrire Int 9, 103 (1993): Ogawa M+, GanToKagukuRyoho(Japanese) 20, 897 (1993): Ogawa M+, GanToKagukuRyoho(Japanese) 20, 907 (1991): Hollingshead LM+, Drugs 42, 690 (1988): Gillies H+, Cancer Chemother Pharmacol 21, 261 (1986): Dodion P+, Invest New Drugs 4, 31 (1986): Lopez M+, Invest New Drugs 4, 39 Nails Nails – pigmentation (1997): Borecky Derrick J+, Cutis 59, 203 Other Injection-site urticaria IDEBENONE Synonym: 6-(10-hydroxydecyl)-2,3-dimethoxy-5-methyl-1,4benzoquinone Trade names: Avan; Mnesis Indications: Alzheimer’s dementia, cardiovascular disease, cerebrovascular disease, demyelination, depression, Friedreich’s ataxia, improving memory, Leber’s hereditary optic neuropathy Category: Coenzyme Q10 analog Half-life: N/A Clinically important, potentially hazardous interactions with: None None IDURSULFASE Reactions Trade name: Elaprase (Shire) Indications: Hunter syndrome, Mucopolysaccharidosis II Category: Enzyme Half-life: 46 minutes Clinically important, potentially hazardous interactions with: N/A Reactions Skin Pruritus (28%) Rash (sic) (13%) Urticaria (16%) Eyes Visual disturbances (22%) Other Anaphylactoid reactions/Anaphylaxis Application-site edema (13%) Fever (63%) Hypersensitivity IFOSFAMIDE Trade names: Holoxan; Ifex (Bristol-Myers Squibb); Ifoxan; Mitoxana; Tronoxal Indications: Cancers, sarcomas, leukemias, lymphomas Category: Alkylating agent Half-life: 4–15 hours Clinically important, potentially hazardous interactions with: aldesleukin, aprepitant Reactions Skin Allergic reactions (sic) (1–10%) Dermatitis (1–10%) Pigmentation (1–10%) (1994): Yule SM+, Cancer 73, 240 (1993): Teresi ME+, Cancer 71, 2873

(1994): Halpern SM, Arch Dermatol 130, 259 (passim)<br />

(1993): Litt JZ, Beachwood, OH (personal case) (observation)<br />

(1987): Shelley ED+, JAmAcadDermatol17, 1057<br />

(1985): Bigby M+, JAmAcadDermatol12, 866<br />

(1984): Stern RS+, JAMA 252, 1433<br />

(1982): Bailin PL+, Clinics in Rheumatic Diseases WB Saunders 8,<br />

493 (passim)<br />

Vasculitis<br />

(2001): Davidson KA+, Cutis 67, 303 (bullous leukocytoclastic)<br />

(1996): Peters F+, J Rheumatol 23, 2008<br />

(1994): Halpern SM, Arch Dermatol 130, 259 (passim)<br />

(1992): Breathnach SM+, Adverse <strong>Drug</strong> Reactions <strong>and</strong> the Skin<br />

Blackwell, Oxford, 186 (passim)<br />

(1985): Bigby M+, JAmAcadDermatol12, 866<br />

(1984): Stern R+, JAMA 252, 1433<br />

(1982): Labbe A+, Ann Dermatol Venereol (French) 109, 995<br />

Vesiculobullous eruption<br />

(1992): Breathnach SM+, Adverse <strong>Drug</strong> Reactions <strong>and</strong> the Skin<br />

Blackwell, Oxford, 186 (passim)<br />

(1988): Laing VB+, JAmAcadDermatol19, 91 (passim)<br />

Wound complications<br />

(1988): Proper SA+, JAmAcadDermatol18, 1173<br />

Mucosal<br />

Aphthous stomatitis<br />

Gingival ulceration (

logo

products

Resources

Company

Terms of service
Privacy policy
Cookie policy
Cookie settings
Imprint
Change language
Made with love in Switzerland
© 2024 Yumpu.com all rights reserved

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!